Liquidia ( $LQDA) Drops -58% After Patent Ruling: Key Factors Behind the Move (See the latest news for any ticker on Tickeron.) LQDA fell roughly 58% over the last 30 days, from a close of $68.63 on September 3, 2026, to $28.64 on October 2, 2026. The collapse was triggered by a September 30 federal court ruling that Yutrepia infringes two valid claims of United Therapeutics' '327 patent. Rival United Therapeutics (UTHR) rallied sharply on the news, while analysts at BofA, BTIG, and Raymond James cut ratings or price targets on Liquidia. The court has not yet set a remedy; outcomes could range from a label change to an injunction restricting Yutrepia's availability. Liquidia plans to appeal the decision and to ask the FDA to remove the PH-ILD indication from Yutrepia's label. $UNCY $GOSS $VIR $KROS $MNKD
published
Liquidia ( $LQDA) Drops -58% After Patent Ruling: Key Factors Behind the Move (See the latest news for any ticker on Tickeron.) LQDA fell roughly 58% over the last 30 days, from a close of $68.63 on September 3, 2026, to $28.64 on October 2, 2026. The collapse
$LQDA$UNCY$GOSS$VIR$KROS$MNKD
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.